These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 11336586)

  • 1. Potential therapeutic application of antisense oligonucleotides in the treatment of ocular diseases.
    Danis RP; Henry SP; Ciulla TA
    Expert Opin Pharmacother; 2001 Feb; 2(2):277-91. PubMed ID: 11336586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Setting sights on the treatment of ocular angiogenesis using antisense oligonucleotides.
    Henry SP; Marcusson EG; Vincent TM; Dean NM
    Trends Pharmacol Sci; 2004 Oct; 25(10):523-7. PubMed ID: 15380936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.
    Henry SP; Miner RC; Drew WL; Fitchett J; York-Defalco C; Rapp LM; Levin AA
    Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2646-51. PubMed ID: 11581212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.
    Fattal E; Bochot A
    Adv Drug Deliv Rev; 2006 Nov; 58(11):1203-23. PubMed ID: 17097190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraocular delivery of oligonucleotides.
    Gomes Dos Santos AL; Bochot A; Fattal E
    Curr Pharm Biotechnol; 2005 Feb; 6(1):7-15. PubMed ID: 15727552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oligonucleotide therapeutics - an emerging novel class of compounds].
    Wacheck V
    Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
    White PJ; Anastasopoulos F; Pouton CW; Boyd BJ
    Expert Rev Mol Med; 2009 Mar; 11():e10. PubMed ID: 19302730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards genomic drug therapy with antisense oligonucleotides.
    Lönnberg H; Vuorio E
    Ann Med; 1996 Dec; 28(6):511-22. PubMed ID: 9017110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleic-acid therapeutics: basic principles and recent applications.
    Opalinska JB; Gewirtz AM
    Nat Rev Drug Discov; 2002 Jul; 1(7):503-14. PubMed ID: 12120257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense oligonucleotides as therapeutic agents.
    Alama A; Barbieri F; Cagnoli M; Schettini G
    Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in antisense oligonucleotide therapeutics.
    Crooke ST; Bennett CF
    Annu Rev Pharmacol Toxicol; 1996; 36():107-29. PubMed ID: 8725384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GEM 132. Gene expression modulation 132.
    Drugs R D; 1999 Nov; 2(5):313-4. PubMed ID: 10728469
    [No Abstract]   [Full Text] [Related]  

  • 16. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P; Temsamani J
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The application of antisense technology in ophthalmology].
    Guo Y; Ge J
    Yan Ke Xue Bao; 1998 Jun; 14(2):108-15. PubMed ID: 12580046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense oligonucleotide pharmacokinetics and metabolism.
    Geary RS
    Expert Opin Drug Metab Toxicol; 2009 Apr; 5(4):381-91. PubMed ID: 19379126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic oligonucleotides as therapeutics: the coming of age.
    Ma DD; Rede T; Naqvi NA; Cook PD
    Biotechnol Annu Rev; 2000; 5():155-96. PubMed ID: 10875000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo.
    Wang L; Prakash RK; Stein CA; Koehn RK; Ruffner DE
    Antisense Nucleic Acid Drug Dev; 2003; 13(3):169-89. PubMed ID: 12954117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.